Galderma R&D
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Galderma R&D sits in the top decile of US sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count).
Galderma R&D: 158 sponsored US clinical trials, 7 recruiting.
Galderma R&D sponsors 158 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 142 completed. 90 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 7 trials.
Top-decile sponsor footprint
Galderma R&D ranks in the top decile of sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
142 of 146 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
158 total, page 4 of 4
Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%
NCT00437151
Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma
NCT00469183
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
NCT00304239
A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam
NCT00436540
Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis
NCT00437216
Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
NCT00469755
Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects
NCT00446043
Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
NCT00472108
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 24 |
| Phase 3 | 41 |
| Phase 4 | 49 |
Therapeutic Areas
Where Galderma R&D enrollment is open (later-stage tilt)
7 recruiting of 158 indexed (4% open); 142 completed (90%).
Phase mix: 90 late (III/IV) vs 28 early (I/II) (later-stage heavy).
Top condition: Acne Vulgaris (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Galderma R&D: open-pipeline peers nationwide
Peers matched on 158 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Galderma R&D sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 158 trials (± recruiting share)
- Pfizer's Upjohn has merged with Mylan to form Viatris · 158 trials · 0% recruiting
- Ann & Robert H Lurie Children's Hospital of Chicago · 159 trials · 19% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Alexion Pharmaceuticals · 162 trials · 10% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 4% recruiting · 45 trials
- Craig L Slingluff, Jr · 4% recruiting · 23 trials
- Esperion Therapeutics · 4% recruiting · 23 trials
- Tonix Pharmaceuticals · 4% recruiting · 23 trials
Related
What to do with this Galderma R&D page
158 registered trials is a research-attention snapshot, not an endorsement of Galderma R&D or any single study.
- 7 of Galderma R&D's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acne Vulgaris is the condition Galderma R&D studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Galderma R&D pipeline card: 158 registered trials from official public datasets.Report a data error.